|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Principles & ConceptsPrinciples & ConceptsThe purpose of this section is to provide definitions of biosafety concepts. Biohazardous MaterialBiohazardous materials are any microorganism, or infectious substance, or any naturally occurring, bioengineered, or synthesized component of any such microorganism or infectious substance, capable of causing:
These include, but are not limited to:
Examples include:
Specifically excluded from this definition is all non-rDNA BSL-1 research activities. Pathogenicity or VirulencePathogenicity or virulence is the ability of a biohazardous material to produce or develop a rapid, severe, or deadly disease. Some materials are highly pathogenic, even in healthy adults, whereas others are opportunistic pathogens able to infect only hosts with lowered immunity or sites other than their normal habitat. Some biohazardous materials are attenuated, or weakened, and do not produce significant disease. The more severe the potentially acquired disease, the higher the risks. Routes of EntryAn infection occurs when pathogenic microorganisms enter the human body in sufficient numbers and by a particular route which overcomes the body’s defense system. By understanding the mode of transmission (pathway from source to you) and route of entry (entry route into body), procedures or controls to prevent exposure and infection can be developed. Inhalation hazards: Inhalation of aerosolized biohazardous materials is the most common route of entry into the body. Inhalation of aerosols involves microscopic solid or liquid particles small enough to remain dispersed and suspended in air for long periods of time. Sources of aerosols include:
Ingestion hazards: Ingestion of biohazardous materials occurs frequently as the result of poor personal hygiene and poor laboratory practice. Proper hand washing minimizes the opportunity for mouth and eye exposures. Examples of how ingestion occurs include:
Direct (Skin/Eye) Contact hazards: Direct contact to biohazardous materials occurs through cross-contamination and mucous membrane exposure including the skin, eyes, inside of the mouth, nose, and the genitals. The main avenues by which biohazardous materials enter the body through the skin are hair follicles, sebaceous glands, sweat glands, and cuts or abrasions. Examples of how ingestion occurs include:
Injection or inoculation hazards: Inoculation or injection occurs when biohazardous material is accidentally introduced into the body with contaminated objects through the intact skin barrier. Inadequate control of sharp instruments and infected animals or arthropod vectors usually results in accidental inoculation or injection. Examples of injection and inoculation hazards include:
Agent Stability or ViabilityStability and viability refer to the ability of a biohazardous material to retain its biohazardous characteristics such as aerosol infectivity and survival time in environment. Factors such as temperature, humidity, pH, oxygen, sunlight or ultraviolet light, chemical disinfectants, growth factors (food reservoir or media), and competition with endemic organisms must be considered. Infectious DoseThe infectious dose is the number of microorganisms required to initiate an infection. This dose can range from one to hundreds of thousands of units depending on agent, exposure route, virulence, and host immune status or susceptibility for the disease. Concentration (Amount of Agent)Concentration is the number of infectious organisms per unit volume. As the viable agent concentration and volume increases, the risk potential gets higher. The media/reservoir, laboratory activity, volume (especially >10 liters) need to be considered in risk determination. Immune StatusImmune status is the current condition of a living organism to resist and overcome infection or disease. The primary function of the immune system is to protect the body from foreign substances by an acquired ability to distinguish self from non-self. Host susceptibility or immune status helps determine the level of risk of acquiring a disease upon exposure. CDC and NIH guidelines presume a population of immuno-competent individuals. Laboratory Biosafety Level CriteriaThere are four recommended laboratory biosafety levels. The biosafety levels consist of laboratory practices, safety equipment, and facilities combinations which are specifically appropriate for the operations performed, suspected routes of biohazardous material transmission, and laboratory function or activity. Biosafety Level 1 (BSL-1)
Biosafety Level 2 (BSL-2)
Biosafety Level 3 (BSL-3)
Biosafety Level 4 (BSL-4)
Vertebrate Animal Biosafety Level CriteriaThere are four recommended vertebrate animal biosafety levels. The recommendations below describe practices, safety equipment and facilities for experiments with animals infected with agents that cause, or may cause, human infection. In general, the biosafety level recommended for working with biohazardous material in vivo and in vitro are comparable. Animal Biosafety Level 1 (ABSL-1)
Animal Biosafety Level 2 (ABSL-2)
Animal Biosafety Level 3 ABSL-3
Animal Biosafety Level 4 (ABSL-4)
Recombinant DNA Biosafety Level CriteriaThe following are NIH requirements for Campus Research with Recombinant DNA in humans, animals, and plants. The investigator must make an initial risk assessment based on the Risk Group (RG) of an agent. Agents are classified into four Risk Groups (RGs) according to their relative pathogenicity for healthy adult humans by the following criteria: Risk Group 1 (RG1): agents are not associated with disease in healthy adults. Risk Group 2 (RG2): agents are associated with human disease that is rarely serious and for which preventive or therapeutic interventions are often available. Risk Group 3 (RG3): agents are associated with serious or lethal human disease for which preventive or therapeutic interventions may be available. Risk Group 4 (RG4): agents are likely to cause serious or lethal human disease for which preventive or therapeutic interventions are not usually available. NIH Guidelines also address physical and biological containment for Recombinant DNA research involving humans, animals, plants and large scale use, including standard microbiological practices, special practices, containment equipment and laboratory facilities.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||